B

Beijing Succeeder Technology Inc
SSE:688338

Watchlist Manager
Beijing Succeeder Technology Inc
SSE:688338
Watchlist
Price: 30.08 CNY -0.56% Market Closed
Market Cap: ¥3.2B

P/E

32.4
Current
14%
More Expensive
vs 3-y average of 28.6

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
32.4
=
Market Cap
¥3.6B
/
Net Income
¥98.3m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
32.4
=
Market Cap
¥3.6B
/
Net Income
¥98.3m

Valuation Scenarios

Beijing Succeeder Technology Inc is trading above its 3-year average

If P/E returns to its 3-Year Average (28.6), the stock would be worth ¥26.5 (12% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-13%
Maximum Upside
+3%
Average Downside
8%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 32.4 ¥30.08
0%
3-Year Average 28.6 ¥26.5
-12%
5-Year Average 28.2 ¥26.19
-13%
Industry Average 33.5 ¥31.08
+3%
Country Average 29.6 ¥27.47
-9%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
¥3.6B
/
Jul 2025
¥98.3m
=
32.4
Current
¥3.6B
/
Dec 2025
¥127.6m
=
27.9
Forward
¥3.6B
/
Dec 2026
¥149m
=
23.9
Forward
¥3.6B
/
Dec 2027
¥170.5m
=
20.9
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Market Distribution

In line with most companies in China
Percentile
53nd
Based on 5 557 companies
53nd percentile
32.4
Low
0 — 17.1
Typical Range
17.1 — 57.7
High
57.7 —
Distribution Statistics
China
Min 0
30th Percentile 17.1
Median 29.6
70th Percentile 57.7
Max 43 569.3

Beijing Succeeder Technology Inc
Glance View

Market Cap
3.2B CNY
Industry
Health Care

Beijing Succeeder Technology, Inc. engages in research, development, production, and sales of detection instruments, reagents, and consumables for thrombosis and hemostasis in the in-vitro diagnosis field. The company is headquartered in Beijing, Beijing and currently employs 266 full-time employees. The company went IPO on 2020-08-06. The firm provides medical institutions with automated detection equipment for blood coagulation, blood rheology, hematocrit, platelet aggregation, and supporting reagents and consumables. Its products include testing instruments, reagents and consumables, such as automatic coagulation testers, coagulation quality control kits, Newtonian fluid quality controls, reaction cups and SAW blood rheology special cleaning. The firm operates its businesses within the domestic market and to overseas markets.

Intrinsic Value
27.99 CNY
Overvaluation 7%
Intrinsic Value
Price ¥30.08
B
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett